Potential role of oral DPP-4 inhibitors in the ADA/EASD consensus statement algorithm for achieving and maintaining tight glycaemic control in type 2 diabetes: recommendations for oral antidiabetic agents

Hyperglycemia plays an important role in the pathogenesis of type 2 diabetes mellitus, i.e., glucotoxicity, and it also is the major risk factor for microvascular complications. Thus, effective glycemic control will not only reduce the incidence of microvascular complications but also correct some of the metabolic abnormalities that contribute to the progression of the disease. Achieving durable tight glycemic control is challenging because of progressive β-cell failure and is hampered by increased frequency of side effects, e.g., hypoglycemia and weight gain. Most recently, inhibitors of the renal sodium-glucose cotransporter have been developed to produce glucosuria and reduce the plasma glucose concentration. These oral antidiabetic agents have the potential to improve glycemic control while avoiding hypoglycemia, to correct the glucotoxicity, and to promote weight loss. In this review, we will summarize the available data concerning the mechanism of action, efficacy, and safety of this novel antidiabetic therapeutic approach.

Download Full-text

Assessing the health-related quality of life in type 2 diabetes patients treated with insulin and oral antidiabetic agents

Wiener klinische Wochenschrift ◽

10.1007/s00508-019-01573-0 ◽

2019 ◽

Cited By ~ 1

Author(s):

Nawras Al-Taie ◽

Delia Maftei ◽

Alexandra Kautzky-Willer ◽

Michael Krebs ◽

Harald Stingl

Keyword(s):

Quality Of Life ◽

Type 2 Diabetes ◽

Health Related Quality ◽

Oral Antidiabetic Agents ◽

Antidiabetic Agents ◽

Oral Antidiabetic ◽

Related Quality ◽

Health Related

Download Full-text

Sodium–Glucose Co-transporter 2 Inhibition – A Novel Strategy for Glucose Control in Type 2 Diabetes

European Endocrinology ◽

10.17925/ee.2011.07.01.30 ◽

2010 ◽

Vol 7 (1) ◽

pp. 30

Author(s):

Luke Norton ◽

Ralph A DeFronzo ◽

Muhammad A Abdul-Ghani ◽

◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Beta Cell ◽

Mechanism Of Action ◽

Microvascular Complications ◽

Oral Antidiabetic Agents ◽

Oral Antidiabetic ◽

Tissue Sensitivity ◽

Novel Strategy

In addition to its central role in the development of microvascular complications, hyperglycaemia plays an important role in the pathogenesis of type 2 diabetes, i.e. glucotoxicity. Thus, effective glycaemic control not only reduces the incidence of microvascular complications, but also corrects the metabolic abnormalities that contribute to the progression of the disease. Progressive beta-cell failure and side effects associated with therapy, such as hypoglycaemia and weight gain, present obstacles to the achievement of optimal durable glycaemic control in subjects with type 2 diabetes. Most recently, inhibitors of the renal sodium glucose co-transporter have been developed to produce glucosuria and reduce the plasma glucose concentration. Because the mechanism of action of these oral antidiabetic agents is independent of beta-cell and tissue sensitivity to insulin, they improve glycaemic control while avoiding hypoglycaemia and promoting weight loss. In this article, we will summarise the available data concerning the mechanism of action, efficacy and safety of this novel antidiabetic therapeutic approach.

Download Full-text